Johnson Financial Group Inc (Wisconsin)’s Neurocrine Biosciences NBIX Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16	Closed	-$2.27K	–	945
2025 Q4	$2.27K	Sell	16 -9	-36%	-$1.3K	﹤0.01%	797
2025 Q3	$3.51K	Buy	+25	New	+$3.39K	﹤0.01%	876
2024 Q3	–	Sell	-10	Closed	-$1.38K	–	1001
2024 Q2	$1.38K	Buy	+10	New	+$1.37K	﹤0.01%	698
2022 Q1	–	Sell	-144	Closed	-$12K	–	766
2021 Q4	$12K	Buy	+144	New	+$13.2K	﹤0.01%	607

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s NBIX Position: Q1 2026 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 16 shares — an estimated $2.27K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in NBIX in Q4 2021 and held it in 4 quarters. The position peaked at $12K in Q4 2021. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Johnson Financial Group Inc (Wisconsin) reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Johnson Financial Group Inc (Wisconsin) sold 16 Neurocrine Biosciences shares in Q1 2026, an estimated $2.27K.
Johnson Financial Group Inc (Wisconsin) first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 4 quarters.
Johnson Financial Group Inc (Wisconsin)'s Neurocrine Biosciences position peaked at $12K in Q4 2021.
700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2026, filed 7 May 2026.